Reata Pharmaceuticals Garners $60,500,000 New Financing

  • Feed Type
  • Date
    5/26/2016
  • Company Name
    Reata Pharmaceuticals
  • Mailing Address
    2801 Gateway Drive Irving, TX 75063 USA
  • Company Description
    Reata Pharmaceuticals, Inc. (NASDAQ: RETA) is a biopharmaceutical company focused on developing novel treatments for cancer, inflammation, and neurodegenerative diseases.
  • Website
    http://www.reatapharma.com
  • Transaction Type
    IPO
  • Transaction Amount
    $60,500,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    We intend to use the net proceeds from this offering as follows: approximately $30 million to advance the development of bardoxolone methyl through a Phase 3 clinical trial for the treatment of CTD-PAH; approximately $6 million to advance the development of bardoxolone methyl through Phase 2 clinical programs for the treatment of four etiologies of PH-ILD; approximately $15 million to advance the development of omaveloxolone, including completion of the MOXIe and MOTOR Phase 2 clinical trials; and the remainder for working capital and other general purposes, including our preclinical studies and clinical trials, although we have not allocated specific dollar amounts to such purposes.
  • M&A Terms

Trending on Xconomy